NCT04675021 - Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions

Cancer

Interventions

DRUG

AZD6094 (Savolitinib) film coated tablets 600 mg

AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3

DRUG

[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)

14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)

DRUG

[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)

14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)

Trial Locations (1)

Research Site, Ruddington